SOURCE: InvestorIdeas.com

InvestorIdeas.com

June 27, 2011 13:04 ET

Biotech/Pharma Stocks Battle for the Sexual Health Market: BioSante Pharmaceuticals, (NASDAQ: BPAX), Pfizer, Teva Pharmaceutical, Watson

BioSante Pharmaceutical (BPAX) Positioned to Be First to Market With LibiGel for Female Sexual Dysfunction (FSD)

POINT ROBERTS, WA--(Marketwire - Jun 27, 2011) - Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features a sector snapshot of biotech/pharma stocks in the sexual dysfunction and sexual health markets.

The competition is heating up in the men's sexual dysfunction market for Pfizer 's Viagra but there is only one Biotech/Pharma company postured to be first to market in the women's sexual health market, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), with LibiGel, a testosterone gel in late-stage Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD).

There is a lot of money on the table in the men's erectile dysfunction market, with Viagra generating revenues of $1.93 billion for Pfizer in 2010. Pfizer Inc is battling it out in court with Teva Pharmaceutical and Watson Pharmaceuticals for generic versions of Viagra. Teva has announced it plans to make generic versions of Viagra in 2012, when the basic Pfizer patent expires. More info http://www.fiercepharma.com/story/pfizer-just-might-postpone-viagras-patent-cliff/2011-06-13

Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals (NASDAQ: BPAX), recently commented in an Investorideas.com interview, "We believe the potential market for products to treat women's sexual health is well over $1 billion in the U.S. alone. We also believe that LibiGel will be the first product approved for the treatment of menopausal women in this indication. Being first to market will result in gaining the majority of the available market."
http://www.investorideas.com/news/2011/main/06073.asp

Investor Spotlight forBioSante Pharmaceuticals (NASDAQ: BPAX):

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. www.biosantepharma.com.

Read the full article at Investorideas.com
http://www.investorideas.com/CO/BPAX/news/2011/06271.asp

To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, please contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com

For Media:
McKinney/Chicago
Alan Zachary
312-506-5220; azachary@mckinneychicago.com

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector.
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Contact Information